Amgen (AMGN) stock had a bullish inflow of $55.35 million worth of trades on uptick and an outflow of $52.47 million in downticks on Monday. The total uptick to downtick ratio stood at 1.05. The net money flow into the stock was $2.88 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $3.9 million. An inflow of $2.61 million block trade was recorded on downticks. $6.51 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 2.49 in favor of the bulls. However, Amgen (AMGN) stock traded down $0.14 , and reached $163.14, a drop of -0.09% over the previous day. On a weekly basis, the stock is 1.27%, over the previous weeks close.
Amgen Inc. is up 1.42% in the last 3-month period. Year-to-Date the stock performance stands at 1.73%. Shares of Amgen Inc. rose by 1.72% in the last five trading days and 6.98% for the last 4 weeks. In a related news,The officer (EVP, Operations) of Amgen Inc, Balachandran Madhavan sold 30,000 shares at $154.12 on May 4, 2016. The Insider selling transaction had a total value worth of $4,623,600. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Amgen (NASDAQ:AMGN): On Mondays trading session , Opening price of the stock was $163.82 with an intraday high of $164. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $162.79. However, the stock managed to close at $162.93, a loss of 0.21% for the day. On the previous day, the stock had closed at $163.28. The total traded volume of the day was 1,815,610 shares.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.